Science & evidence
Peer-reviewed science, validated prospectively.
Mirnow's tests rest on published research by our team, and on a prospective multicentre study now under way.
Selected publications
- 2026Peer-reviewed
Urinary exosomal let-7c cluster in bladder cancer
BMC Cancer
Proof of concept for a urine miRNA signature in bladder cancer.
- 2026Preprint
Multi-compartment miRNA study in prostate cancer
medRxiv (preprint, not yet peer reviewed)
Urinary exosomal miRNA combined with PSA and age in prostate cancer.
- 2025Peer-reviewed
Blood 3-miRNA panel with machine learning
Scientific Reports 15:30477
In a prospective cohort, the blood panel distinguished prostate cancer from BPH better than PSA alone.
- 2024Peer-reviewed
gQuant: selecting stable qPCR reference genes
Scientific Reports 14:18774
Open-source tool for selecting stable qPCR reference genes.
- 2023Peer-reviewed
Urinary extracellular-vesicle miRNAs in prostate cancer (review)
Frontiers in Genetics 14:1065757
Review of urinary extracellular-vesicle miRNAs in prostate cancer.
Clinical validation programme
How we are validating the test
- Prospective, multicentre study at leading Indian institutions.
- Planned enrolment of about 600 participants.
- Primary endpoint: detection of clinically significant prostate cancer, against biopsy as the reference standard.
- Pre-specified model lock before an independent, held-out validation set.
- Approved by institutional ethics committees; trial registration with CTRI.
Join the validation study.
We are expanding our multicentre programme with urologists and hospitals across India.